Context Therapeutics Inc.
CNTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.24
KIRA · Stoqly’s AI analyst, in plain words
- Context Therapeutics Inc. lost $36.1M in fiscal 2025.
- Free cash flow was −$26.4M in fiscal 2025, — of revenue.
Market cap
$22.8M
P/E
—
Revenue
—
Net income
−$36.1M
Free cash flow
−$26.4M
Operating margin
—
Context Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$36.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Context Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Context Therapeutics Inc.
- CIK
- 0001842952
Context Therapeutics Inc. · CNTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.1M | $0.5M | $1.2M | — | — |
| Revenue growth | — | — | 112.7% | — | — |
| Net interest income | −$0.1M | $0.5M | $1.2M | — | — |
| Operating margin | 16,395.3% | −2,810.4% | −2,154.0% | — | — |
| Net income | −$10.5M | −$14.8M | −$24.0M | −$26.7M | −$36.1M |
| Net margin | 16,288.0% | −2,710.7% | −2,058.8% | — | — |
| Diluted EPS | −$3.69 | −$0.93 | −$1.50 | −$0.46 | −$0.38 |
| Cash | |||||
| Cash from operations | −$8.8M | −$13.5M | −$21.0M | −$14.6M | −$26.4M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.8M | −$13.6M | −$21.0M | −$14.6M | −$26.4M |
| FCF margin | 13,706.4% | −2,482.4% | −1,808.2% | — | — |
| Share count change | 37.9% | 463.4% | 0.0% | 265.9% | 62.9% |
| Debt and strength | |||||
| Cash and short-term investments | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Shareholders' equity | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
| Current ratio | 16.9x | 11.8x | 3.8x | 35.6x | 8.5x |
| Interest coverage | −164.0x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −66.7% | −35.7% | −102.8% | −49.9% | −46.4% |
| Return on tangible equity | −21.7% | −42.7% | −201.9% | −28.1% | −59.7% |
| Piotroski F-score | — | 2 | 3 | — | — |
| Altman Z'' | 19.6 | 10.9 | −16.5 | 36.1 | 3.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Context Therapeutics Inc. · CNTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.24 a share, the company is worth $22.8M.
Source: SEC EDGAR XBRL filings (CIK 0001842952). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.